ID   PPBT_HUMAN              Reviewed;         524 AA.
AC   P05186; A1A4E7; B2RMP8; B7Z387; B7Z4Y6; O75090; Q2TAI7; Q59EJ7;
AC   Q5BKZ5; Q5VTG5; Q6NZI8; Q8WU32; Q9UBK0;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   21-JUN-2005, sequence version 4.
DT   10-MAY-2017, entry version 203.
DE   RecName: Full=Alkaline phosphatase, tissue-nonspecific isozyme;
DE            Short=AP-TNAP;
DE            Short=TNSALP;
DE            EC=3.1.3.1 {ECO:0000269|PubMed:23688511, ECO:0000269|PubMed:25982064};
DE   AltName: Full=Alkaline phosphatase liver/bone/kidney isozyme;
DE   Flags: Precursor;
GN   Name=ALPL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Osteosarcoma;
RX   PubMed=3532105; DOI=10.1073/pnas.83.19.7182;
RA   Weiss M.J., Henthorn P.S., Lafferty M.A., Slaughter C., Raducha M.,
RA   Harris H.;
RT   "Isolation and characterization of a cDNA encoding a human
RT   liver/bone/kidney-type alkaline phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7182-7186(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Osteosarcoma;
RX   PubMed=3165380;
RA   Weiss M.J., Ray K., Henthorn P.S., Lamb B., Kadesch T., Harris H.;
RT   "Structure of the human liver/bone/kidney alkaline phosphatase gene.";
RL   J. Biol. Chem. 263:12002-12010(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HIS-263.
RC   TISSUE=Liver;
RX   PubMed=2928120; DOI=10.1093/nar/17.5.2129;
RA   Kishi F., Matsuura S., Kajii T.;
RT   "Nucleotide sequence of the human liver-type alkaline phosphatase
RT   cDNA.";
RL   Nucleic Acids Res. 17:2129-2129(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HOPS PHE-289.
RX   PubMed=9747027; DOI=10.1007/s100380050061;
RA   Sugimoto N., Iwamoto S., Hoshino Y., Kajii E.;
RT   "A novel missense mutation of the tissue-nonspecific alkaline
RT   phosphatase gene detected in a patient with hypophosphatasia.";
RL   J. Hum. Genet. 43:160-164(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   HIS-152.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   HIS-263.
RC   TISSUE=Brain, Cerebellum, Lymphoma, and Peripheral nerve;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 18-49.
RC   TISSUE=Liver;
RX   PubMed=3954357; DOI=10.1016/0003-9861(86)90223-7;
RA   Garattini E., Hua J.-C., Pan Y.C.E., Udenfriend S.;
RT   "Human liver alkaline phosphatase, purification and partial
RT   sequencing: homology with the placental isozyme.";
RL   Arch. Biochem. Biophys. 245:331-337(1986).
RN   [11]
RP   PROTEIN SEQUENCE OF 18-32, AND GLYCOSYLATION.
RX   PubMed=1458595;
RA   Nishihara Y., Hayashi Y., Adachi T., Koyama I., Stigbrand T.,
RA   Hirano K.;
RT   "Chemical nature of intestinal-type alkaline phosphatase in human
RT   kidney.";
RL   Clin. Chem. 38:2539-2542(1992).
RN   [12]
RP   GPI-ANCHOR [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=14517339; DOI=10.1074/mcp.M300079-MCP200;
RA   Elortza F., Nuehse T.S., Foster L.J., Stensballe A., Peck S.C.,
RA   Jensen O.N.;
RT   "Proteomic analysis of glycosylphosphatidylinositol-anchored membrane
RT   proteins.";
RL   Mol. Cell. Proteomics 2:1261-1270(2003).
RN   [13]
RP   GPI-ANCHOR [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16602701; DOI=10.1021/pr050419u;
RA   Elortza F., Mohammed S., Bunkenborg J., Foster L.J., Nuehse T.S.,
RA   Brodbeck U., Peck S.C., Jensen O.N.;
RT   "Modification-specific proteomics of plasma membrane proteins:
RT   identification and characterization of glycosylphosphatidylinositol-
RT   anchored proteins released upon phospholipase D treatment.";
RL   J. Proteome Res. 5:935-943(2006).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-430.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   VARIANT HOPS THR-179.
RX   PubMed=3174660; DOI=10.1073/pnas.85.20.7666;
RA   Weiss M.J., Cole D.E.C., Ray K., Whyte M.P., Lafferty M.A.,
RA   Mulivor R.A., Harris H.;
RT   "A missense mutation in the human liver/bone/kidney alkaline
RT   phosphatase gene causing a lethal form of hypophosphatasia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7666-7669(1988).
RN   [17]
RP   VARIANTS HOPS VAL-33; CYS-71; PRO-71; LYS-191; PRO-207; ALA-294;
RP   VAL-378 AND HIS-436, AND VARIANT HIS-263.
RX   PubMed=1409720; DOI=10.1073/pnas.89.20.9924;
RA   Henthorn P.S., Raducha M., Fedde K.N., Lafferty M.A., Whyte M.P.;
RT   "Different missense mutations at the tissue-nonspecific alkaline
RT   phosphatase gene locus in autosomal recessively inherited forms of
RT   mild and severe hypophosphatasia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:9924-9928(1992).
RN   [18]
RP   VARIANT HOPS ASP-334.
RX   PubMed=8406453; DOI=10.1006/geno.1993.1305;
RA   Greenberg C.R., Taylor C.L., Haworth J.C., Seargeant L.E.,
RA   Philipps S., Triggs-Raine B., Chodirker B.N.;
RT   "A homoallelic Gly317-->Asp mutation in ALPL causes the perinatal
RT   (lethal) form of hypophosphatasia in Canadian mennonites.";
RL   Genomics 17:215-217(1993).
RN   [19]
RP   INVOLVEMENT IN HOPSI, AND VARIANT HOPSI LYS-298.
RX   PubMed=7833929; DOI=10.1093/hmg/3.9.1683;
RA   Orimo H., Hayashi Z., Watanabe A., Hirayama T., Hirayama T.,
RA   Shimada T.;
RT   "Novel missense and frameshift mutations in the tissue-nonspecific
RT   alkaline phosphatase gene in a Japanese patient with
RT   hypophosphatasia.";
RL   Hum. Mol. Genet. 3:1683-1684(1994).
RN   [20]
RP   INVOLVEMENT IN HOPSI, AND VARIANTS HOPSI LEU-327 AND ARG-456.
RX   PubMed=8954059; DOI=10.1210/jcem.81.12.8954059;
RA   Ozono K., Yamagata M., Michigami T., Nakajima S., Sakai N., Cai G.,
RA   Satomura K., Yasui N., Okada S., Nakayama M.;
RT   "Identification of novel missense mutations (Phe310Leu and Gly439Arg)
RT   in a neonatal case of hypophosphatasia.";
RL   J. Clin. Endocrinol. Metab. 81:4458-4461(1996).
RN   [21]
RP   VARIANTS HOPS PHE-17; VAL-40; SER-75; ARG-120; ARG-129; ASP-170;
RP   TRP-184; LYS-191; TRP-223; LYS-291; ASP-334; PRO-445; CYS-450; SER-473
RP   AND ARG-491, AND VARIANT HIS-263.
RX   PubMed=9781036; DOI=10.1038/sj.ejhg.5200190;
RA   Mornet E., Taillandier A., Peyramaure S., Kaper F., Muller F.,
RA   Brenner R., Bussiere P., Freisinger P., Godard J., Le Merrer M.,
RA   Oury J.F., Plauchu H., Puddu R., Rival J.M., Superti-Furga A.,
RA   Touraine R.L., Serre J.L., Simon-Bouy B.;
RT   "Identification of fifteen novel mutations in the tissue-nonspecific
RT   alkaline phosphatase (TNSALP) gene in European patients with severe
RT   hypophosphatasia.";
RL   Eur. J. Hum. Genet. 6:308-314(1998).
RN   [22]
RP   VARIANTS HOPS THR-111; THR-177; GLY-191; LEU-327 AND ILE-382.
RX   PubMed=9452105;
RA   Goseki-Sone M., Orimo H., Iimura T., Takagi Y., Watanabe H.,
RA   Taketa K., Sato S., Mayanagi H., Shimada T., Oida S.;
RT   "Hypophosphatasia: identification of five novel missense mutations
RT   (G507A, G705A, A748G, T1155C, G1320A) in the tissue-nonspecific
RT   alkaline phosphatase gene among Japanese patients.";
RL   Hum. Mutat. Suppl. 1:S263-S267(1998).
RN   [23]
RP   VARIANTS HOPS VAL-40; LEU-62; SER-75; THR-111; ARG-120; ARG-129;
RP   HIS-136; VAL-162; ASP-170; TYR-171; TRP-184; LYS-191; TRP-223;
RP   VAL-249; LYS-291; VAL-306; ASP-334; CYS-391; PRO-445; CYS-450;
RP   SER-473; LYS-476 AND ARG-491, 3D-STRUCTURE MODELING, AND
RP   CHARACTERIZATION OF VARIANTS.
RX   PubMed=10332035; DOI=10.1093/hmg/8.6.1039;
RA   Zurutuza L., Muller F., Gibrat J.F., Taillandier A., Simon-Bouy B.,
RA   Serre J.L., Mornet E.;
RT   "Correlations of genotype and phenotype in hypophosphatasia.";
RL   Hum. Mol. Genet. 8:1039-1046(1999).
RN   [24]
RP   VARIANTS HOPS LEU-62; HIS-136; VAL-162; TYR-171; LYS-191; TYR-201;
RP   VAL-249; VAL-306 AND LYS-476.
RX   PubMed=10094560;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:2<171::AID-HUMU16>3.0.CO;2-T;
RA   Taillandier A., Zurutuza L., Muller F., Simon-Bouy B., Serre J.L.,
RA   Bird L., Brenner R., Boute O., Cousin J., Gaillard D., Heidemann P.H.,
RA   Steinmann B., Wallot M., Mornet E.;
RT   "Characterization of eleven novel mutations (M45L, R119H, 544delG,
RT   G145V, H154Y, C184Y, D289V, 862+5A, 1172delC, R411X, E459K) in the
RT   tissue-nonspecific alkaline phosphatase (TNSALP) gene in patients with
RT   severe hypophosphatasia.";
RL   Hum. Mutat. 13:171-172(1999).
RN   [25]
RP   VARIANTS HOPSI GLU-224 AND CYS-426.
RX   PubMed=10834525; DOI=10.1007/s004310051290;
RA   Mochizuki H., Saito M., Michigami T., Ohashi H., Koda N.,
RA   Yamaguchi S., Ozono K.;
RT   "Severe hypercalcaemia and respiratory insufficiency associated with
RT   infantile hypophosphatasia caused by two novel mutations of the
RT   tissue-nonspecific alkaline phosphatase gene.";
RL   Eur. J. Pediatr. 159:375-379(2000).
RN   [26]
RP   VARIANTS HOPS VAL-40; THR-111; ASN-134; THR-176; LYS-191; TYR-201;
RP   SER-246; THR-348; ARG-381; GLY-406; HIS-450; ILE-478 AND SER-489.
RX   PubMed=10679946;
RX   DOI=10.1002/(SICI)1098-1004(200003)15:3<293::AID-HUMU11>3.0.CO;2-Q;
RA   Taillandier A., Cozien E., Muller F., Merrien Y., Bonnin E.,
RA   Fribourg C., Simon-Bouy B., Serre J.L., Bieth E., Brenner R.,
RA   Cordier M.P., De Bie S., Fellmann F., Freisinger P., Hesse V.,
RA   Hennekam R.C.M., Josifova D., Kerzin-Storrar L., Leporrier N.,
RA   Zabot M.-T., Mornet E.;
RT   "Fifteen new mutations (-195C>T, L-12X, 298-2A>G, T117N, A159T, R229S,
RT   997+2T>A, E274X, A331T, H364R, D389G, 1256delC, R433H, N461I, C472S)
RT   in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in
RT   patients with hypophosphatasia.";
RL   Hum. Mutat. 15:293-293(2000).
RN   [27]
RP   VARIANT HOPS VAL-378, AND VARIANT ALA-522.
RX   PubMed=10690885; DOI=10.1210/jcem.85.2.6373;
RA   Mueller H.L., Yamazaki M., Michigami T., Kageyama T., Schoenau E.,
RA   Schneider P., Ozono K.;
RT   "Asp361Val mutant of alkaline phosphatase found in patients with
RT   dominantly inherited hypophosphatasia inhibits the activity of the
RT   wild-type enzyme.";
RL   J. Clin. Endocrinol. Metab. 85:743-747(2000).
RN   [28]
RP   VARIANT HOPS SER-417.
RX   PubMed=11745997; DOI=10.1002/ajmg.1541.abs;
RA   Sergi C., Mornet E., Troeger J., Voigtlaender T.;
RT   "Perinatal hypophosphatasia: radiology, pathology and molecular
RT   biology studies in a family harboring a splicing mutation (648+1A) and
RT   a novel missense mutation (N400S) in the tissue-nonspecific alkaline
RT   phosphatase (TNSALP) gene.";
RL   Am. J. Med. Genet. 103:235-240(2001).
RN   [29]
RP   CHARACTERIZATION OF VARIANTS HOPS VAL-40; VAL-63; THR-116; LEU-181;
RP   TRP-184; TRP-223; VAL-249; VAL-378; ILE-478 AND PHE-490.
RX   PubMed=11479741; DOI=10.1007/s004390100546;
RA   Lia-Baldini A.S., Muller F., Taillandier A., Gibrat J.F., Mouchard M.,
RA   Robin B., Simon-Bouy B., Serre J.L., Aylsworth A.S., Bieth E.,
RA   Delanote S., Freisinger P., Hu J.C.-C., Krohn H.-P., Nunes M.E.,
RA   Mornet E.;
RT   "A molecular approach to dominance in hypophosphatasia.";
RL   Hum. Genet. 109:99-108(2001).
RN   [30]
RP   VARIANTS HOPSI CYS-28 AND MET-459, AND VARIANTS HOPS VAL-40; VAL-51;
RP   HIS-71; THR-116; HIS-136; HIS-152; THR-176; THR-179; LYS-191; ASP-211;
RP   VAL-220; GLY-235; TYR-294; GLY-327; SER-399 AND ALA-423.
RX   PubMed=11438998; DOI=10.1002/humu.1154;
RA   Taillandier A., Lia-Baldini A.S., Mouchard M., Robin B., Muller F.,
RA   Simon-Bouy B., Serre J.L., Bera-Louville A., Bonduelle M.,
RA   Eckhardt J., Gaillard D., Myhre A.G., Koertge-Jung S., Larget-Piet L.,
RA   Malou E., Sillence D., Temple I.K., Viot G., Mornet E.;
RT   "Twelve novel mutations in the tissue-nonspecific alkaline phosphatase
RT   gene (ALPL) in patients with various forms of hypophosphatasia.";
RL   Hum. Mutat. 18:83-84(2001).
RN   [31]
RP   INVOLVEMENT IN HOPSC, VARIANTS HOPSC MET-68; SER-71; THR-177; TRP-223;
RP   PRO-275 AND HIS-391, CHARACTERIZATION OF VARIANTS HOPSC MET-68;
RP   SER-71; THR-177; TRP-223; PRO-275 AND HIS-391, VARIANT ALA-522, AND
RP   CHARACTERIZATION OF VARIANT ALA-522.
RX   PubMed=11760847; DOI=10.1359/jbmr.2001.16.12.2313;
RA   Orimo H., Girschick H.J., Goseki-Sone M., Ito M., Oda K., Shimada T.;
RT   "Mutational analysis and functional correlation with phenotype in
RT   German patients with childhood-type hypophosphatasia.";
RL   J. Bone Miner. Res. 16:2313-2319(2001).
RN   [32]
RP   VARIANT HOPS VAL-132.
RX   PubMed=11834095; DOI=10.1034/j.1601-0825.2001.00740.x;
RA   Watanabe H., Hashimoto-Uoshima M., Goseki-Sone M., Orimo H.,
RA   Ishikawa I.;
RT   "A novel point mutation (C571T) in the tissue-non-specific alkaline
RT   phosphatase gene in a case of adult-type hypophosphatasia.";
RL   Oral Dis. 7:331-335(2001).
RN   [33]
RP   VARIANTS HOPS LYS-291 AND ARG-326.
RX   PubMed=11999978; DOI=10.1023/A:1015121414782;
RA   Litmanovitz I., Reish O., Dolfin T., Arnon S., Regev R., Grinshpan G.,
RA   Yamazaki M., Ozono K.;
RT   "Glu274Lys/Gly309Arg mutation of the tissue-nonspecific alkaline
RT   phosphatase gene in neonatal hypophosphatasia associated with
RT   convulsions.";
RL   J. Inherit. Metab. Dis. 25:35-40(2002).
RN   [34]
RP   VARIANTS HOPS SER-51; HIS-71; THR-111; MET-128; HIS-134; HIS-136;
RP   THR-176; LYS-191; GLN-223; TRP-223; SER-246; ALA-294; PRO-299; PHE-327
RP   DEL; ARG-339; THR-348; VAL-378; MET-414; ASP-426 AND LYS-476, AND
RP   VARIANTS HIS-263 AND ALA-522.
RX   PubMed=11855933; DOI=10.1006/mgme.2001.3283;
RA   Mumm S., Jones J., Finnegan P., Henthorn P.S., Podgornik M.N.,
RA   Whyte M.P.;
RT   "Denaturing gradient gel electrophoresis analysis of the tissue
RT   nonspecific alkaline phosphatase isoenzyme gene in hypophosphatasia.";
RL   Mol. Genet. Metab. 75:143-153(2002).
RN   [35]
RP   VARIANTS HOPS VAL-62; ARG-63; THR-111; ILE-148; SER-162; GLU-189;
RP   ALA-220; LEU-272; GLY-293-294-ASP DEL; LYS-311; LYS-452 AND THR-468.
RX   PubMed=12815606; DOI=10.1002/humu.9159;
RA   Spentchian M., Merrien Y., Herasse M., Dobbie Z., Glaeser D.,
RA   Holder S.E., Ivarsson S.-A., Kostiner D., Mansour S., Norman A.,
RA   Roth J., Stipoljev F., Taillemite J.-L., van der Smagt J.J.,
RA   Serre J.-L., Simon-Bouy B., Taillandier A., Mornet E.;
RT   "Severe hypophosphatasia: characterization of fifteen novel mutations
RT   in the ALPL gene.";
RL   Hum. Mutat. 22:105-106(2003).
RN   [36]
RP   VARIANTS HOPS LEU-108; THR-116 AND MET-414, AND CHARACTERIZATION OF
RP   VARIANT HOPS LEU-108.
RX   PubMed=12920074; DOI=10.1136/jmg.40.8.605;
RA   Herasse M., Spentchian M., Taillandier A., Keppler-Noreuil K.,
RA   Fliorito A.N.M., Bergoffen J., Wallerstein R., Muti C., Simon-Bouy B.,
RA   Mornet E.;
RT   "Molecular study of three cases of odontohypophosphatasia resulting
RT   from heterozygosity for mutations in the tissue non-specific alkaline
RT   phosphatase gene.";
RL   J. Med. Genet. 40:605-609(2003).
RN   [37]
RP   VARIANT HOPS GLY-114.
RX   PubMed=15135428; DOI=10.1016/j.arcped.2004.02.018;
RA   Draguet C., Gillerot Y., Mornet E.;
RT   "Childhood hypophosphatasia: a case report due to a novel mutation.";
RL   Arch. Pediatr. 11:440-443(2004).
RN   [38]
RP   VARIANTS HOPS VAL-33; HIS-136; GLN-223; TRP-223; HIS-272; THR-292;
RP   ALA-294; THR-295; ASP-297; ASP-334 AND ALA-411, AND CHARACTERIZATION
RP   OF VARIANTS HOPS VAL-33; HIS-272; THR-292; THR-295; ASP-297 AND
RP   ALA-411.
RX   PubMed=15694177; DOI=10.1016/j.ymgme.2004.11.003;
RA   Brun-Heath I., Taillandier A., Serre J.-L., Mornet E.;
RT   "Characterization of 11 novel mutations in the tissue non-specific
RT   alkaline phosphatase gene responsible for hypophosphatasia and
RT   genotype-phenotype correlations.";
RL   Mol. Genet. Metab. 84:273-277(2005).
RN   [39]
RP   VARIANTS HOPS CYS-71; HIS-71; THR-111; THR-176; LYS-191; ARG-334;
RP   ASP-334; ARG-339; ILE-382; CYS-391; HIS-391; MET-414; ALA-420;
RP   LYS-452; LEU-459 AND ALA-476, AND CHARACTERIZATION OF VARIANTS HOPS
RP   CYS-71; HIS-71; THR-111; THR-176; LYS-191; ARG-334; ASP-334; ARG-339;
RP   ILE-382; CYS-391; HIS-391; MET-414; LYS-452; LEU-459 AND ALA-476.
RX   PubMed=19500388; DOI=10.1186/1471-2350-10-51;
RA   Fauvert D., Brun-Heath I., Lia-Baldini A.S., Bellazi L.,
RA   Taillandier A., Serre J.L., de Mazancourt P., Mornet E.;
RT   "Mild forms of hypophosphatasia mostly result from dominant negative
RT   effect of severe alleles or from compound heterozygosity for severe
RT   and moderate alleles.";
RL   BMC Med. Genet. 10:51-51(2009).
RN   [40]
RP   VARIANTS HOPS TYR-201 AND SER-489, AND CHARACTERIZATION OF VARIANTS
RP   HOPS TYR-201 AND SER-489.
RX   PubMed=22266140; DOI=10.1016/j.bbadis.2012.01.007;
RA   Satou Y., Al-Shawafi H.A., Sultana S., Makita S., Sohda M., Oda K.;
RT   "Disulfide bonds are critical for tissue-nonspecific alkaline
RT   phosphatase function revealed by analysis of mutant proteins bearing a
RT   C(201)-Y or C(489)-S substitution associated with severe
RT   hypophosphatasia.";
RL   Biochim. Biophys. Acta 1822:581-588(2012).
RN   [41]
RP   CHARACTERIZATION OF VARIANTS HOPS SER-420 AND ALA-420.
RX   PubMed=23039266; DOI=10.1111/febs.12022;
RA   Makita S., Al-Shawafi H.A., Sultana S., Sohda M., Nomura S., Oda K.;
RT   "A dimerization defect caused by a glycine substitution at position
RT   420 by serine in tissue-nonspecific alkaline phosphatase associated
RT   with perinatal hypophosphatasia.";
RL   FEBS J. 279:4327-4337(2012).
RN   [42]
RP   CHARACTERIZATION OF VARIANT HOPS SER-417, SUBUNIT, SUBCELLULAR
RP   LOCATION, AND CATALYTIC ACTIVITY.
RX   PubMed=23688511; DOI=10.1016/j.ymgme.2013.04.016;
RA   Sultana S., Al-Shawafi H.A., Makita S., Sohda M., Amizuka N.,
RA   Takagi R., Oda K.;
RT   "An asparagine at position 417 of tissue-nonspecific alkaline
RT   phosphatase is essential for its structure and function as revealed by
RT   analysis of the N417S mutation associated with severe
RT   hypophosphatasia.";
RL   Mol. Genet. Metab. 109:282-288(2013).
RN   [43]
RP   CHARACTERIZATION OF VARIANT HOPS LEU-108, SUBCELLULAR LOCATION,
RP   SUBUNIT, AND CATALYTIC ACTIVITY.
RX   PubMed=25982064; DOI=10.1016/j.ymgme.2015.05.006;
RA   Numa-Kinjoh N., Komaru K., Ishida Y., Sohda M., Oda K.;
RT   "Molecular phenotype of tissue-nonspecific alkaline phosphatase with a
RT   proline (108) to leucine substitution associated with dominant
RT   odontohypophosphatasia.";
RL   Mol. Genet. Metab. 115:180-185(2015).
CC   -!- FUNCTION: This isozyme may play a role in skeletal mineralization.
CC   -!- CATALYTIC ACTIVITY: A phosphate monoester + H(2)O = an alcohol +
CC       phosphate. {ECO:0000255|PROSITE-ProRule:PRU10042,
CC       ECO:0000269|PubMed:23688511, ECO:0000269|PubMed:25982064}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P05187};
CC       Note=Binds 1 Mg(2+) ion. {ECO:0000250|UniProtKB:P05187};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:P05187};
CC       Note=Binds 2 Zn(2+) ions. {ECO:0000250|UniProtKB:P05187};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:23688511,
CC       ECO:0000269|PubMed:25982064}.
CC   -!- INTERACTION:
CC       Q99558:MAP3K14; NbExp=4; IntAct=EBI-1054354, EBI-358011;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23688511,
CC       ECO:0000269|PubMed:25982064}; Lipid-anchor, GPI-anchor
CC       {ECO:0000269|PubMed:23688511, ECO:0000269|PubMed:25982064}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P05186-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P05186-2; Sequence=VSP_042711;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P05186-3; Sequence=VSP_044228;
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:1458595,
CC       ECO:0000269|PubMed:19159218}.
CC   -!- DISEASE: Hypophosphatasia (HOPS) [MIM:146300]: A metabolic bone
CC       disease characterized by defective skeletal mineralization and
CC       biochemically by deficient activity of the tissue non-specific
CC       isoenzyme of alkaline phosphatase. Four forms are distinguished,
CC       depending on the age of onset: perinatal, infantile, childhood and
CC       adult type. The perinatal form is the most severe and is almost
CC       always fatal. The adult form is mild and characterized by
CC       recurrent fractures, osteomalacia, rickets, and loss of teeth.
CC       Some cases are asymptomatic, while some patients manifest dental
CC       features without skeletal manifestations (odontohypophosphatasia).
CC       {ECO:0000269|PubMed:10094560, ECO:0000269|PubMed:10332035,
CC       ECO:0000269|PubMed:10679946, ECO:0000269|PubMed:10690885,
CC       ECO:0000269|PubMed:10834525, ECO:0000269|PubMed:11438998,
CC       ECO:0000269|PubMed:11479741, ECO:0000269|PubMed:11745997,
CC       ECO:0000269|PubMed:11760847, ECO:0000269|PubMed:11834095,
CC       ECO:0000269|PubMed:11855933, ECO:0000269|PubMed:11999978,
CC       ECO:0000269|PubMed:12815606, ECO:0000269|PubMed:12920074,
CC       ECO:0000269|PubMed:1409720, ECO:0000269|PubMed:15135428,
CC       ECO:0000269|PubMed:15694177, ECO:0000269|PubMed:19500388,
CC       ECO:0000269|PubMed:22266140, ECO:0000269|PubMed:23039266,
CC       ECO:0000269|PubMed:23688511, ECO:0000269|PubMed:25982064,
CC       ECO:0000269|PubMed:3174660, ECO:0000269|PubMed:7833929,
CC       ECO:0000269|PubMed:8406453, ECO:0000269|PubMed:8954059,
CC       ECO:0000269|PubMed:9452105, ECO:0000269|PubMed:9747027,
CC       ECO:0000269|PubMed:9781036}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hypophosphatasia childhood type (HOPSC) [MIM:241510]: A
CC       bone disease characterized by defective skeletal mineralization
CC       and biochemically by deficient activity of the tissue non-specific
CC       isoenzyme of alkaline phosphatase. {ECO:0000269|PubMed:11760847}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Hypophosphatasia infantile type (HOPSI) [MIM:241500]: A
CC       severe bone disease characterized by defective skeletal
CC       mineralization and biochemically by deficient activity of the
CC       tissue non-specific isoenzyme of alkaline phosphatase. Three more
CC       or less distinct types of infantile hypophosphatasia can be
CC       identified: (1) type 1 with onset in utero or in early postnatal
CC       life, craniostenosis, severe skeletal abnormalities,
CC       hypercalcemia, and death in the first year or so of life; (2) type
CC       2 with later, more gradual development of symptoms, moderately
CC       severe 'rachitic' skeletal changes and premature loss of teeth;
CC       (3) type 3 with no symptoms, the condition being determined on
CC       routine studies. {ECO:0000269|PubMed:10834525,
CC       ECO:0000269|PubMed:11438998, ECO:0000269|PubMed:7833929,
CC       ECO:0000269|PubMed:8954059}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the alkaline phosphatase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD93051.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=ALPL; Note=Tissue nonspecific alkaline
CC       phosphatase gene mutations database;
CC       URL="http://www.sesep.uvsq.fr/Database.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alkaline phosphatase entry;
CC       URL="https://en.wikipedia.org/wiki/Alkaline_phosphatase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M24439; AAB59378.1; -; Genomic_DNA.
DR   EMBL; M24429; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24430; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24431; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24432; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24433; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24434; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24435; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24436; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24437; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24438; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; X14174; CAA32376.1; -; mRNA.
DR   EMBL; AB011406; BAA32129.1; -; mRNA.
DR   EMBL; AK295608; BAH12123.1; -; mRNA.
DR   EMBL; AK298085; BAH12722.1; -; mRNA.
DR   EMBL; AB209814; BAD93051.1; ALT_INIT; mRNA.
DR   EMBL; AL592309; CAH72079.1; -; Genomic_DNA.
DR   EMBL; AL359815; CAH72079.1; JOINED; Genomic_DNA.
DR   EMBL; AL359815; CAI16259.1; -; Genomic_DNA.
DR   EMBL; AL592309; CAI16259.1; JOINED; Genomic_DNA.
DR   EMBL; CH471134; EAW94977.1; -; Genomic_DNA.
DR   EMBL; BC021289; AAH21289.3; -; mRNA.
DR   EMBL; BC066116; AAH66116.2; -; mRNA.
DR   EMBL; BC090861; AAH90861.2; -; mRNA.
DR   EMBL; BC110909; AAI10910.2; -; mRNA.
DR   EMBL; BC126165; AAI26166.1; -; mRNA.
DR   EMBL; BC136325; AAI36326.1; -; mRNA.
DR   CCDS; CCDS217.1; -. [P05186-1]
DR   CCDS; CCDS53274.1; -. [P05186-2]
DR   CCDS; CCDS53275.1; -. [P05186-3]
DR   PIR; S03613; PAHUH.
DR   RefSeq; NP_000469.3; NM_000478.5. [P05186-1]
DR   RefSeq; NP_001120973.2; NM_001127501.3. [P05186-3]
DR   RefSeq; NP_001170991.1; NM_001177520.2. [P05186-2]
DR   RefSeq; XP_005245875.1; XM_005245818.1. [P05186-1]
DR   RefSeq; XP_006710609.1; XM_006710546.2. [P05186-1]
DR   UniGene; Hs.75431; -.
DR   ProteinModelPortal; P05186; -.
DR   SMR; P05186; -.
DR   BioGrid; 106750; 5.
DR   IntAct; P05186; 6.
DR   STRING; 9606.ENSP00000363965; -.
DR   BindingDB; P05186; -.
DR   ChEMBL; CHEMBL5979; -.
DR   DrugBank; DB01143; Amifostine.
DR   DrugBank; DB06716; Fospropofol.
DR   DEPOD; P05186; -.
DR   iPTMnet; P05186; -.
DR   PhosphoSitePlus; P05186; -.
DR   BioMuta; ALPL; -.
DR   DMDM; 68067533; -.
DR   EPD; P05186; -.
DR   MaxQB; P05186; -.
DR   PaxDb; P05186; -.
DR   PeptideAtlas; P05186; -.
DR   PRIDE; P05186; -.
DR   DNASU; 249; -.
DR   Ensembl; ENST00000374832; ENSP00000363965; ENSG00000162551. [P05186-1]
DR   Ensembl; ENST00000374840; ENSP00000363973; ENSG00000162551. [P05186-1]
DR   Ensembl; ENST00000539907; ENSP00000437674; ENSG00000162551. [P05186-2]
DR   Ensembl; ENST00000540617; ENSP00000442672; ENSG00000162551. [P05186-3]
DR   GeneID; 249; -.
DR   KEGG; hsa:249; -.
DR   UCSC; uc001bet.4; human. [P05186-1]
DR   CTD; 249; -.
DR   DisGeNET; 249; -.
DR   GeneCards; ALPL; -.
DR   GeneReviews; ALPL; -.
DR   HGNC; HGNC:438; ALPL.
DR   HPA; CAB020829; -.
DR   HPA; HPA007105; -.
DR   HPA; HPA008765; -.
DR   MalaCards; ALPL; -.
DR   MIM; 146300; phenotype.
DR   MIM; 171760; gene.
DR   MIM; 241500; phenotype.
DR   MIM; 241510; phenotype.
DR   neXtProt; NX_P05186; -.
DR   OpenTargets; ENSG00000162551; -.
DR   Orphanet; 247676; Adult hypophosphatasia.
DR   Orphanet; 247667; Childhood-onset hypophosphatasia.
DR   Orphanet; 247651; Infantile hypophosphatasia.
DR   Orphanet; 247685; Odontohypophosphatasia.
DR   Orphanet; 247623; Perinatal lethal hypophosphatasia.
DR   Orphanet; 247638; Prenatal benign hypophosphatasia.
DR   PharmGKB; PA24729; -.
DR   eggNOG; KOG4126; Eukaryota.
DR   eggNOG; COG1785; LUCA.
DR   GeneTree; ENSGT00390000008704; -.
DR   HOVERGEN; HBG007345; -.
DR   InParanoid; P05186; -.
DR   KO; K01077; -.
DR   OMA; YTYVTTG; -.
DR   OrthoDB; EOG091G067H; -.
DR   PhylomeDB; P05186; -.
DR   TreeFam; TF323513; -.
DR   BRENDA; 3.1.3.1; 2681.
DR   Reactome; R-HSA-163125; Post-translational modification: synthesis of GPI-anchored proteins.
DR   SABIO-RK; P05186; -.
DR   SIGNOR; P05186; -.
DR   ChiTaRS; ALPL; human.
DR   GeneWiki; ALPL; -.
DR   GenomeRNAi; 249; -.
DR   PRO; PR:P05186; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000162551; -.
DR   ExpressionAtlas; P05186; baseline and differential.
DR   Genevisible; P05186; HS.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0065010; C:extracellular membrane-bounded organelle; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:Ensembl.
DR   GO; GO:0004035; F:alkaline phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016462; F:pyrophosphatase activity; IDA:MGI.
DR   GO; GO:0006501; P:C-terminal protein lipidation; TAS:Reactome.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0071529; P:cementum mineralization; IEA:Ensembl.
DR   GO; GO:0003006; P:developmental process involved in reproduction; IEA:Ensembl.
DR   GO; GO:0001958; P:endochondral ossification; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEP:BHF-UCL.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   CDD; cd00016; alkPPc; 1.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR001952; Alkaline_phosphatase.
DR   InterPro; IPR018299; Alkaline_phosphatase_AS.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   PANTHER; PTHR11596; PTHR11596; 1.
DR   Pfam; PF00245; Alk_phosphatase; 1.
DR   PRINTS; PR00113; ALKPHPHTASE.
DR   SMART; SM00098; alkPPc; 1.
DR   SUPFAM; SSF53649; SSF53649; 1.
DR   PROSITE; PS00123; ALKALINE_PHOSPHATASE; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Biomineralization; Cell membrane;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; GPI-anchor; Hydrolase; Lipoprotein;
KW   Magnesium; Membrane; Metal-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Zinc.
FT   SIGNAL        1     17       {ECO:0000269|PubMed:1458595,
FT                                ECO:0000269|PubMed:3954357}.
FT   CHAIN        18    502       Alkaline phosphatase, tissue-nonspecific
FT                                isozyme.
FT                                /FTId=PRO_0000024023.
FT   PROPEP      503    524       Removed in mature form. {ECO:0000305}.
FT                                /FTId=PRO_0000024024.
FT   ACT_SITE    110    110       Phosphoserine intermediate.
FT                                {ECO:0000250|UniProtKB:P05187}.
FT   METAL        60     60       Magnesium.
FT                                {ECO:0000250|UniProtKB:P05187}.
FT   METAL        60     60       Zinc 1. {ECO:0000250|UniProtKB:P05187}.
FT   METAL       110    110       Zinc 1. {ECO:0000250|UniProtKB:P05187}.
FT   METAL       173    173       Magnesium.
FT                                {ECO:0000250|UniProtKB:P05187}.
FT   METAL       332    332       Magnesium.
FT                                {ECO:0000250|UniProtKB:P05187}.
FT   METAL       337    337       Zinc 2. {ECO:0000250|UniProtKB:P05187}.
FT   METAL       341    341       Zinc 2; via tele nitrogen.
FT                                {ECO:0000250|UniProtKB:P05187}.
FT   METAL       378    378       Zinc 1. {ECO:0000250|UniProtKB:P05187}.
FT   METAL       379    379       Zinc 1; via tele nitrogen.
FT                                {ECO:0000250|UniProtKB:P05187}.
FT   METAL       454    454       Zinc 2; via tele nitrogen.
FT                                {ECO:0000250|UniProtKB:P05187}.
FT   MOD_RES     110    110       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P09242}.
FT   LIPID       502    502       GPI-anchor amidated serine.
FT                                {ECO:0000305}.
FT   CARBOHYD    140    140       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    230    230       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    271    271       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    303    303       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    430    430       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   DISULFID    139    201       {ECO:0000250|UniProtKB:P05187}.
FT   DISULFID    489    497       {ECO:0000250|UniProtKB:P05187}.
FT   VAR_SEQ       1     99       MISPFLVLAIGTCLTNSLVPEKEKDPKYWRDQAQETLKYAL
FT                                ELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPG
FT                                EETRLEMDKFPFVALSK -> MPWSFRSSTPTWLRMSSCSW
FT                                EM (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042711.
FT   VAR_SEQ       1     55       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044228.
FT   VARIANT      17     17       S -> F (in HOPS).
FT                                {ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_025903.
FT   VARIANT      28     28       Y -> C (in HOPSI; 7% of activity).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013972.
FT   VARIANT      33     33       A -> V (in HOPS; 7.2% of wild-type
FT                                activity; dbSNP:rs121918005).
FT                                {ECO:0000269|PubMed:1409720,
FT                                ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_006147.
FT   VARIANT      40     40       A -> V (in HOPS; 2% of activity;
FT                                dbSNP:rs770093969).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11479741,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_011081.
FT   VARIANT      51     51       A -> S (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025904.
FT   VARIANT      51     51       A -> V (in HOPS).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013973.
FT   VARIANT      62     62       M -> L (in HOPS; moderate; 27% of
FT                                activity). {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035}.
FT                                /FTId=VAR_006148.
FT   VARIANT      62     62       M -> V (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025905.
FT   VARIANT      63     63       G -> R (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025906.
FT   VARIANT      63     63       G -> V (in HOPS; loss of activity).
FT                                {ECO:0000269|PubMed:11479741}.
FT                                /FTId=VAR_013974.
FT   VARIANT      68     68       T -> M (in HOPSC; severe allele).
FT                                {ECO:0000269|PubMed:11760847}.
FT                                /FTId=VAR_025907.
FT   VARIANT      71     71       R -> C (in HOPS; 35% of alkaline
FT                                phosphatase activity; dbSNP:rs121918001).
FT                                {ECO:0000269|PubMed:1409720,
FT                                ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_006149.
FT   VARIANT      71     71       R -> H (in HOPS; loss of alkaline
FT                                phosphatase activity).
FT                                {ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_013975.
FT   VARIANT      71     71       R -> P (in HOPS; dbSNP:rs121918003).
FT                                {ECO:0000269|PubMed:1409720}.
FT                                /FTId=VAR_006150.
FT   VARIANT      71     71       R -> S (in HOPSC; severe allele;
FT                                dbSNP:rs121918001).
FT                                {ECO:0000269|PubMed:11760847}.
FT                                /FTId=VAR_025908.
FT   VARIANT      75     75       G -> S (in HOPS; severe; 3.5% of
FT                                activity). {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013976.
FT   VARIANT      76     76       Q -> R (in HOPS).
FT                                /FTId=VAR_025909.
FT   VARIANT     108    108       P -> L (in HOPS; 0.4% of alkaline
FT                                phosphatase activity; severe allele; no
FT                                effect on subcellular location; fails to
FT                                assemble into dimeric structure; dominant
FT                                negative effect; dbSNP:rs28933975).
FT                                {ECO:0000269|PubMed:12920074,
FT                                ECO:0000269|PubMed:25982064}.
FT                                /FTId=VAR_025910.
FT   VARIANT     111    111       A -> T (in HOPS; odonto; 50% of alkaline
FT                                phosphatase activity; dbSNP:rs773257111).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:12815606,
FT                                ECO:0000269|PubMed:19500388,
FT                                ECO:0000269|PubMed:9452105}.
FT                                /FTId=VAR_006151.
FT   VARIANT     114    114       A -> G (in HOPS).
FT                                {ECO:0000269|PubMed:15135428}.
FT                                /FTId=VAR_025911.
FT   VARIANT     116    116       A -> T (in HOPS; loss of alkaline
FT                                phosphatase activity; dbSNP:rs28933974).
FT                                {ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11479741,
FT                                ECO:0000269|PubMed:12920074,
FT                                ECO:0000269|PubMed:25982064}.
FT                                /FTId=VAR_013977.
FT   VARIANT     120    120       G -> R (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013978.
FT   VARIANT     128    128       V -> M (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025912.
FT   VARIANT     129    129       G -> R (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013979.
FT   VARIANT     132    132       A -> V (in HOPS).
FT                                {ECO:0000269|PubMed:11834095}.
FT                                /FTId=VAR_013146.
FT   VARIANT     134    134       T -> H (in HOPS; requires 2 nucleotide
FT                                substitutions; dbSNP:rs786204530).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025913.
FT   VARIANT     134    134       T -> N (in HOPS; 9% of activity;
FT                                dbSNP:rs780583917).
FT                                {ECO:0000269|PubMed:10679946}.
FT                                /FTId=VAR_011082.
FT   VARIANT     136    136       R -> H (in HOPS; moderate; 33% of
FT                                activity; dbSNP:rs121918011).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_006152.
FT   VARIANT     148    148       T -> I (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025914.
FT   VARIANT     152    152       R -> H (in HOPS; dbSNP:rs149344982).
FT                                {ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_013980.
FT   VARIANT     162    162       G -> S (in HOPS; dbSNP:rs760029254).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025915.
FT   VARIANT     162    162       G -> V (in HOPS; severe; 1% of activity;
FT                                dbSNP:rs121918012).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035}.
FT                                /FTId=VAR_006153.
FT   VARIANT     170    170       N -> D (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013981.
FT   VARIANT     171    171       H -> R (in HOPS; dbSNP:rs778232217).
FT                                /FTId=VAR_025916.
FT   VARIANT     171    171       H -> Y (in HOPS; severe; 2% of activity).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035}.
FT                                /FTId=VAR_006154.
FT   VARIANT     176    176       A -> T (in HOPS; 30% of alkaline
FT                                phosphatase activity; dbSNP:rs121918019).
FT                                {ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_011083.
FT   VARIANT     177    177       A -> T (in HOPS and HOPSC; moderate
FT                                allele; dbSNP:rs199669988).
FT                                {ECO:0000269|PubMed:11760847,
FT                                ECO:0000269|PubMed:9452105}.
FT                                /FTId=VAR_006155.
FT   VARIANT     179    179       A -> T (in HOPS; dbSNP:rs121918000).
FT                                {ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:3174660}.
FT                                /FTId=VAR_006156.
FT   VARIANT     181    181       S -> L (in HOPS; 1% of activity;
FT                                dbSNP:rs199590449).
FT                                {ECO:0000269|PubMed:11479741}.
FT                                /FTId=VAR_013982.
FT   VARIANT     184    184       R -> W (in HOPS; loss of activity;
FT                                dbSNP:rs763159520).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11479741,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013983.
FT   VARIANT     189    189       D -> E (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025917.
FT   VARIANT     191    191       E -> G (in HOPS; odonto).
FT                                {ECO:0000269|PubMed:9452105}.
FT                                /FTId=VAR_006157.
FT   VARIANT     191    191       E -> K (in HOPS; moderate; frequent
FT                                mutation in European countries; 56% of
FT                                alkaline phosphatase activity;
FT                                dbSNP:rs121918007).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:1409720,
FT                                ECO:0000269|PubMed:19500388,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_006158.
FT   VARIANT     201    201       C -> Y (in HOPS; weak alkaline
FT                                phosphatase activity; severely affects
FT                                homodimerization; reduced cell surface
FT                                expression).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:22266140}.
FT                                /FTId=VAR_006159.
FT   VARIANT     207    207       Q -> P (in HOPS; dbSNP:rs121918004).
FT                                {ECO:0000269|PubMed:1409720}.
FT                                /FTId=VAR_006160.
FT   VARIANT     211    211       N -> D (in HOPS).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013984.
FT   VARIANT     212    212       I -> F (in HOPS).
FT                                /FTId=VAR_025918.
FT   VARIANT     220    220       G -> A (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025919.
FT   VARIANT     220    220       G -> V (in HOPS; odonto).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013985.
FT   VARIANT     223    223       R -> Q (in HOPS; dbSNP:rs199665722).
FT                                {ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025920.
FT   VARIANT     223    223       R -> W (in HOPS and HOPSC; 3% of
FT                                activity; severe allele;
FT                                dbSNP:rs766076920).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11479741,
FT                                ECO:0000269|PubMed:11760847,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:15694177,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013986.
FT   VARIANT     224    224       K -> E (in HOPSI; partial loss of
FT                                activity). {ECO:0000269|PubMed:10834525}.
FT                                /FTId=VAR_011084.
FT   VARIANT     235    235       E -> G (in HOPS).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013987.
FT   VARIANT     246    246       R -> S (in HOPS; 4% of activity).
FT                                {ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_011085.
FT   VARIANT     249    249       G -> V (in HOPS; partial loss of
FT                                activity; dbSNP:rs121918018).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11479741}.
FT                                /FTId=VAR_013988.
FT   VARIANT     263    263       Y -> H (common polymorphism;
FT                                dbSNP:rs3200254).
FT                                {ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:1409720,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2928120,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_006161.
FT   VARIANT     272    272       R -> H (in HOPS; 6.8% of wild-type
FT                                activity; dbSNP:rs781272386).
FT                                {ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025921.
FT   VARIANT     272    272       R -> L (in HOPS; dbSNP:rs781272386).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025922.
FT   VARIANT     275    275       L -> P (in HOPSC; severe allele).
FT                                {ECO:0000269|PubMed:11760847}.
FT                                /FTId=VAR_025923.
FT   VARIANT     289    289       L -> F (in HOPS).
FT                                {ECO:0000269|PubMed:9747027}.
FT                                /FTId=VAR_006162.
FT   VARIANT     291    291       E -> K (in HOPS; moderate; 8% of
FT                                activity; dbSNP:rs786204473).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11999978,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013989.
FT   VARIANT     292    292       P -> T (in HOPS; 4% of wild-type
FT                                activity; dbSNP:rs765458125).
FT                                {ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025924.
FT   VARIANT     293    294       Missing (in HOPS).
FT                                /FTId=VAR_025925.
FT   VARIANT     294    294       D -> A (in HOPS; dbSNP:rs121918002).
FT                                {ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:1409720,
FT                                ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_006163.
FT   VARIANT     294    294       D -> Y (in HOPS).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013990.
FT   VARIANT     295    295       M -> T (in HOPS; 8.5% of wild-type
FT                                activity). {ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025926.
FT   VARIANT     297    297       Y -> D (in HOPS; 1.3% of wild-type
FT                                activity). {ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025927.
FT   VARIANT     298    298       E -> K (in HOPSI; dbSNP:rs121918017).
FT                                {ECO:0000269|PubMed:7833929}.
FT                                /FTId=VAR_025928.
FT   VARIANT     299    299       L -> P (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025929.
FT   VARIANT     306    306       D -> V (in HOPS).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035}.
FT                                /FTId=VAR_006164.
FT   VARIANT     311    311       E -> K (in HOPS; dbSNP:rs763457259).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025930.
FT   VARIANT     326    326       G -> R (in HOPS; in a patient carrying
FT                                also K-291).
FT                                {ECO:0000269|PubMed:11999978}.
FT                                /FTId=VAR_013991.
FT   VARIANT     327    327       F -> G (in HOPS; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013992.
FT   VARIANT     327    327       F -> L (in HOPS and HOPSI;
FT                                dbSNP:rs121918010).
FT                                {ECO:0000269|PubMed:8954059,
FT                                ECO:0000269|PubMed:9452105}.
FT                                /FTId=VAR_006165.
FT   VARIANT     327    327       Missing (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025931.
FT   VARIANT     334    334       G -> D (in HOPS; loss of alkaline
FT                                phosphatase activity; dbSNP:rs121918009).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:15694177,
FT                                ECO:0000269|PubMed:19500388,
FT                                ECO:0000269|PubMed:8406453,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_006166.
FT   VARIANT     334    334       G -> R (in HOPS; weak alkaline
FT                                phosphatase activity).
FT                                {ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_075557.
FT   VARIANT     339    339       G -> R (in HOPS; loss of alkaline
FT                                phosphatase activity).
FT                                {ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_025932.
FT   VARIANT     348    348       A -> T (in HOPS).
FT                                {ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_011086.
FT   VARIANT     354    354       E -> D (in HOPS).
FT                                /FTId=VAR_025933.
FT   VARIANT     378    378       D -> V (in HOPS; loss of activity;
FT                                dbSNP:rs121918008).
FT                                {ECO:0000269|PubMed:10690885,
FT                                ECO:0000269|PubMed:11479741,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:1409720}.
FT                                /FTId=VAR_006167.
FT   VARIANT     381    381       H -> R (in HOPS).
FT                                {ECO:0000269|PubMed:10679946}.
FT                                /FTId=VAR_011087.
FT   VARIANT     382    382       V -> I (in HOPS; loss of alkaline
FT                                phosphatase activity; dbSNP:rs771540767).
FT                                {ECO:0000269|PubMed:19500388,
FT                                ECO:0000269|PubMed:9452105}.
FT                                /FTId=VAR_006168.
FT   VARIANT     391    391       R -> C (in HOPS; moderate; 4-10% of
FT                                alkaline phosphatase activity;
FT                                dbSNP:rs371243939).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_013993.
FT   VARIANT     391    391       R -> H (in HOPSC and HOPS; severe allele;
FT                                loss of alkaline phosphatase activity).
FT                                {ECO:0000269|PubMed:11760847,
FT                                ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_025934.
FT   VARIANT     399    399       A -> S (in HOPS).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013994.
FT   VARIANT     406    406       D -> G (in HOPS; 15% of activity).
FT                                {ECO:0000269|PubMed:10679946}.
FT                                /FTId=VAR_011088.
FT   VARIANT     411    411       T -> A (in HOPS; absence of residual
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025935.
FT   VARIANT     414    414       L -> M (in HOPS; loss of alkaline
FT                                phosphatase activity).
FT                                {ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:12920074,
FT                                ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_025936.
FT   VARIANT     417    417       N -> S (in HOPS; very low alkaline
FT                                phosphatase activity; does not affect
FT                                subcellular location; fails to assemble
FT                                into dimeric structure;
FT                                dbSNP:rs121918014).
FT                                {ECO:0000269|PubMed:11745997,
FT                                ECO:0000269|PubMed:23688511}.
FT                                /FTId=VAR_025937.
FT   VARIANT     420    420       G -> A (in HOPS; very low alkaline
FT                                phosphatase activity; does not affect
FT                                subcellular location).
FT                                {ECO:0000269|PubMed:19500388,
FT                                ECO:0000269|PubMed:23039266}.
FT                                /FTId=VAR_075558.
FT   VARIANT     420    420       G -> S (in HOPS; very low alkaline
FT                                phosphatase activity; does not affect
FT                                subcellular location).
FT                                {ECO:0000269|PubMed:23039266}.
FT                                /FTId=VAR_075559.
FT   VARIANT     423    423       V -> A (in HOPS; 16% alkaline of
FT                                phosphatase activity).
FT                                {ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:23039266}.
FT                                /FTId=VAR_013995.
FT   VARIANT     426    426       G -> C (in HOPSI; partial loss of
FT                                activity). {ECO:0000269|PubMed:10834525}.
FT                                /FTId=VAR_011089.
FT   VARIANT     426    426       G -> D (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025938.
FT   VARIANT     436    436       Y -> H (in HOPS; dbSNP:rs121918006).
FT                                {ECO:0000269|PubMed:1409720}.
FT                                /FTId=VAR_006169.
FT   VARIANT     445    445       S -> P (in HOPS; severe; 2% of activity).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013996.
FT   VARIANT     450    450       R -> C (in HOPS; severe; 4% of activity;
FT                                dbSNP:rs138690664).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013997.
FT   VARIANT     450    450       R -> H (in HOPS; dbSNP:rs150799088).
FT                                {ECO:0000269|PubMed:10679946}.
FT                                /FTId=VAR_011090.
FT   VARIANT     452    452       E -> K (in HOPS; loss of alkaline
FT                                phosphatase activity).
FT                                {ECO:0000269|PubMed:12815606,
FT                                ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_025939.
FT   VARIANT     456    456       G -> R (in HOPSI; loss of activity;
FT                                dbSNP:rs121918016).
FT                                {ECO:0000269|PubMed:8954059}.
FT                                /FTId=VAR_011091.
FT   VARIANT     459    459       V -> L (in HOPS; loss of alkaline
FT                                phosphatase activity).
FT                                {ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_075560.
FT   VARIANT     459    459       V -> M (in HOPSI).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013998.
FT   VARIANT     468    468       A -> T (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025940.
FT   VARIANT     473    473       G -> S (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013999.
FT   VARIANT     476    476       E -> A (in HOPS; loss of alkaline
FT                                phosphatase activity).
FT                                {ECO:0000269|PubMed:19500388}.
FT                                /FTId=VAR_075561.
FT   VARIANT     476    476       E -> K (in HOPS).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_006170.
FT   VARIANT     478    478       N -> I (in HOPS; 9% of activity).
FT                                {ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11479741}.
FT                                /FTId=VAR_011092.
FT   VARIANT     489    489       C -> S (in HOPS; reduces alkaline
FT                                phosphatase activity).
FT                                {ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:22266140}.
FT                                /FTId=VAR_011093.
FT   VARIANT     490    490       I -> F (in HOPS; odonto; partial loss of
FT                                activity). {ECO:0000269|PubMed:11479741}.
FT                                /FTId=VAR_014000.
FT   VARIANT     491    491       G -> R (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_014001.
FT   VARIANT     522    522       V -> A (in dbSNP:rs34605986).
FT                                {ECO:0000269|PubMed:10690885,
FT                                ECO:0000269|PubMed:11760847,
FT                                ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_011094.
FT   CONFLICT     29     29       W -> A (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    104    104       N -> K (in Ref. 3; CAA32376).
FT                                {ECO:0000305}.
FT   CONFLICT    361    361       Q -> H (in Ref. 1; BAA32129).
FT                                {ECO:0000305}.
FT   CONFLICT    446    446       A -> P (in Ref. 1; BAA32129).
FT                                {ECO:0000305}.
SQ   SEQUENCE   524 AA;  57305 MW;  71B45F17F6211900 CRC64;
     MISPFLVLAI GTCLTNSLVP EKEKDPKYWR DQAQETLKYA LELQKLNTNV AKNVIMFLGD
     GMGVSTVTAA RILKGQLHHN PGEETRLEMD KFPFVALSKT YNTNAQVPDS AGTATAYLCG
     VKANEGTVGV SAATERSRCN TTQGNEVTSI LRWAKDAGKS VGIVTTTRVN HATPSAAYAH
     SADRDWYSDN EMPPEALSQG CKDIAYQLMH NIRDIDVIMG GGRKYMYPKN KTDVEYESDE
     KARGTRLDGL DLVDTWKSFK PRYKHSHFIW NRTELLTLDP HNVDYLLGLF EPGDMQYELN
     RNNVTDPSLS EMVVVAIQIL RKNPKGFFLL VEGGRIDHGH HEGKAKQALH EAVEMDRAIG
     QAGSLTSSED TLTVVTADHS HVFTFGGYTP RGNSIFGLAP MLSDTDKKPF TAILYGNGPG
     YKVVGGEREN VSMVDYAHNN YQAQSAVPLR HETHGGEDVA VFSKGPMAHL LHGVHEQNYV
     PHVMAYAACI GANLGHCAPA SSAGSLAAGP LLLALALYPL SVLF
//
